Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
Reza Shojaei, Executive Leader, Strategic Growth Advisor in Health and Biopharma, shared on LinkedIn:
”Are Hemoglobin Oxygen Carriers (HBOCs) a breakthrough waiting to happen, or just hype?
What if we could deliver oxygen without relying on blood donors, refrigeration, or blood typing?
That’s the bold promise of Hemoglobin Oxygen Carriers (HBOCs), sometimes called “artificial blood.”
Approved in South Africa, tested in Japan, funded by the U.S. military, and eyed for organ preservation in Europe… yet still viewed with caution by regulators.
So, are HBOCs a breakthrough waiting to happen, or just hype?’
In this newsletter edition, we explore:
- Where HBOCs stand today
- Their advantages and safety challenges
- Whether they can truly replace blood donation
- What the global market looks like in 2025
- If they’re viable for low- and middle-income countries”
Read the full Blood and Plasma Pulse newsletter edition here.

Stay updated on the emerging in the field of hematology with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?